Multiple antipsychotic medication prescribing patterns

Annals of Pharmacotherapy

Volumn 37, Issue 7-8, 2003, Pages 951-955

  Schumacher, Jennifer E ^a,b   Makela, Eugene H ^c   Griffin, Holly R ^a,d  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b William R Sharpe Jr Hospital   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antipsychotic; Drug use evaluation; Polypharmacy; Psychosis; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG POTENTIATION; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACY; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; GUIDELINES; HUMANS; MALE; MIDDLE AGED; PRESCRIPTIONS, DRUG; PSYCHOTIC DISORDERS; QUESTIONNAIRES;

EID: 0038441936     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C420     Document Type: Article

References (18)

1. Crismon ML, Dorson PG. Schizophrenia. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells Bg, Posey LM. Pharmacotherapy: a pathophysiologic approach. 4th ed. Stamford, CT: Appleton & Lange, 1999:1118-27.
2. Miller AL, Chiles JA, Chiles JK, Crismon ML, Rush AJ, Shon SP. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry 1999;60:649-57.
3. Stahl SM. Antipsychotic polypharmacy. Part 1: therapeutic option or dirty little secret? J Clin Psychiatry 1999;60:425-6.
4. Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. Am J Psychiatry 1997;154(4 suppl):1-63.
5. Bowen GT, Garry M, Sajbel TA. Guidelines for the use of combination antipsychotic medications in a psychiatric setting. P & T 2000;24:297-301.
6. Treatment of schizophrenia: The Expert Consensus. Panel for Schizophrenia. J Clin Psychiatry 1996;57(suppl 12B):3-58.
7. Lehman AF, Steinwachs DM, and the Co-Investigators of the PORT Project. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998;24:1-10.
8. Morrison DP. Management of treatment refractory schizophrenia. Br J Psychiatry 1996;169(suppl 31):15-20.
9. Smith TE, Docherty JP. Standards of care and clinical algorithms for treating schizophrenia. Psychiatr Clin North Am 1998;21:203-20.
10. Stahl SM. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry 1999;60 (suppl 10):31-41.
11. Stahl SM. Antipsychotic polypharmacy. Part 2: tips on use and misuse. J Clin Psychiatry 1999;60:506-7.
12. Stahl SM. Antipsychotic polypharmacy: squandering precious resources? J Clin Psychiatry 2002;63:93-4.
13. Wilson WH, Ban TA, Guy W. Pharmacotherapy of chronic hospitalized schizophrenics: prescription practices. Neuropsychobiology 1985;14:75-82.
14. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry 1999;60(suppl 10):20-30.
15. Procyshyn RM, Kennedy NB, Tse G, Thompson B. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001;46:334-9.
16. Leslie DL, Rosenheck RA. Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors. Med Care 2001;39:923-33.
17. International classification of diseases. 9th rev. Geneva: World Health Organization, 1977.
18. Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, et al. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990;16:551-61.